SG11202102272UA - Oncolytic virus platform to treat hematological cancer - Google Patents
Oncolytic virus platform to treat hematological cancerInfo
- Publication number
- SG11202102272UA SG11202102272UA SG11202102272UA SG11202102272UA SG11202102272UA SG 11202102272U A SG11202102272U A SG 11202102272UA SG 11202102272U A SG11202102272U A SG 11202102272UA SG 11202102272U A SG11202102272U A SG 11202102272UA SG 11202102272U A SG11202102272U A SG 11202102272UA
- Authority
- SG
- Singapore
- Prior art keywords
- oncolytic virus
- hematological cancer
- treat hematological
- virus platform
- platform
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000002489 hematologic effect Effects 0.000 title 1
- 244000309459 oncolytic virus Species 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4725—Proteoglycans, e.g. aggreccan
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862727307P | 2018-09-05 | 2018-09-05 | |
| PCT/US2019/049598 WO2020051248A1 (en) | 2018-09-05 | 2019-09-04 | Oncolytic virus platform to treat hematological cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202102272UA true SG11202102272UA (en) | 2021-04-29 |
Family
ID=69722027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202102272UA SG11202102272UA (en) | 2018-09-05 | 2019-09-04 | Oncolytic virus platform to treat hematological cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210252086A1 (en) |
| EP (1) | EP3846829A4 (en) |
| JP (1) | JP2022524173A (en) |
| KR (1) | KR20210055740A (en) |
| CN (1) | CN112969468A (en) |
| AU (1) | AU2019336180A1 (en) |
| CA (1) | CA3112788A1 (en) |
| IL (1) | IL281252A (en) |
| MX (1) | MX2021002668A (en) |
| SG (1) | SG11202102272UA (en) |
| TW (1) | TW202023582A (en) |
| WO (1) | WO2020051248A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3946373A4 (en) * | 2019-03-28 | 2023-01-11 | Arizona Board of Regents, a Body Corporate of the State of Arizona, acting for and on behalf of Arizona State University | Oncolytic myxoma virus expressing fast p14 to treat hematological cancer |
| JP2022546539A (en) | 2019-09-02 | 2022-11-04 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ | A novel oncolytic virus platform for treating cancer with myxoma virus |
| MX2022004323A (en) * | 2019-10-10 | 2022-08-02 | Univ Arizona State | Oncolytic viruses that express multi-specific immune cell engagers. |
| WO2023192955A2 (en) * | 2022-03-30 | 2023-10-05 | Arizona Board Of Regents On Behalf Of Arizona State University | Cancer therapies comprising a nuclear export inhibitor and an oncolytic virus |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05009526A (en) * | 2003-03-07 | 2005-12-15 | Robarts Res Inst | Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection. |
| CA2565974A1 (en) * | 2004-05-14 | 2005-12-01 | Receptor Biologix, Inc. | Cell surface receptor isoforms and methods of identifying and using the same |
| EP1863906A4 (en) * | 2005-03-07 | 2009-06-03 | Robarts Res Inst | Use of a combination of myxoma virus and rapamycin for therapeutic treatment |
| NZ572893A (en) * | 2006-06-01 | 2011-06-30 | Robarts Res Inst | Myxoma virus mutants for cancer treatment |
| FR2946536B1 (en) * | 2009-06-11 | 2011-07-29 | Agronomique Inst Nat Rech | USE OF AN ATXURATED STRAIN OF MYXOMA VIRUS AS AN ONCOLYTIC |
| AU2011286024B2 (en) * | 2010-08-02 | 2014-08-07 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| WO2014089354A1 (en) * | 2012-12-07 | 2014-06-12 | The Regents Of The University Of California | Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities |
| PL2968520T3 (en) * | 2013-03-14 | 2022-01-03 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor |
| CN106714835A (en) * | 2014-09-17 | 2017-05-24 | 默克专利股份公司 | A method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases |
| JP6797803B2 (en) * | 2014-12-31 | 2020-12-09 | セルジーン コーポレイション | How to use natural killer cells to treat blood disorders, solid tumors, or infectious diseases |
| WO2017210058A1 (en) * | 2016-06-01 | 2017-12-07 | Ibc Pharmaceuticals, Inc. | Combination therapy with t-cell redirecting bispecific antibodies and checkpoint inhibitors |
| WO2018049261A1 (en) * | 2016-09-09 | 2018-03-15 | Icellhealth Consulting Llc | Oncolytic virus expressing immune checkpoint modulators |
| CN110325209A (en) * | 2017-02-24 | 2019-10-11 | 宏观基因有限公司 | CD137 and the bi-specific binding molecule of tumour antigen and application thereof can be combined |
| AU2018223821B2 (en) * | 2017-02-27 | 2022-05-19 | Shattuck Labs, Inc. | TIGIT- and LIGHT-based chimeric proteins |
| CN107164338A (en) * | 2017-06-27 | 2017-09-15 | 镇江市卫克生物科技有限公司 | A kind of recombination oncolytic virus and its application |
| JP2022546539A (en) * | 2019-09-02 | 2022-11-04 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ | A novel oncolytic virus platform for treating cancer with myxoma virus |
-
2019
- 2019-09-04 SG SG11202102272UA patent/SG11202102272UA/en unknown
- 2019-09-04 CN CN201980073063.0A patent/CN112969468A/en active Pending
- 2019-09-04 WO PCT/US2019/049598 patent/WO2020051248A1/en unknown
- 2019-09-04 US US17/274,051 patent/US20210252086A1/en active Pending
- 2019-09-04 JP JP2021512408A patent/JP2022524173A/en active Pending
- 2019-09-04 MX MX2021002668A patent/MX2021002668A/en unknown
- 2019-09-04 AU AU2019336180A patent/AU2019336180A1/en active Pending
- 2019-09-04 EP EP19858456.7A patent/EP3846829A4/en active Pending
- 2019-09-04 CA CA3112788A patent/CA3112788A1/en active Pending
- 2019-09-04 KR KR1020217010051A patent/KR20210055740A/en active Search and Examination
- 2019-09-05 TW TW108132137A patent/TW202023582A/en unknown
-
2021
- 2021-03-04 IL IL281252A patent/IL281252A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3846829A1 (en) | 2021-07-14 |
| US20210252086A1 (en) | 2021-08-19 |
| EP3846829A4 (en) | 2022-09-14 |
| KR20210055740A (en) | 2021-05-17 |
| CA3112788A1 (en) | 2020-03-12 |
| CN112969468A (en) | 2021-06-15 |
| JP2022524173A (en) | 2022-04-28 |
| TW202023582A (en) | 2020-07-01 |
| WO2020051248A1 (en) | 2020-03-12 |
| AU2019336180A1 (en) | 2021-04-15 |
| MX2021002668A (en) | 2021-05-12 |
| IL281252A (en) | 2021-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280459A (en) | Phosphoramidates for the treatment of hepatitis b virus | |
| IL281252A (en) | Oncolytic virus platform to treat hematological cancer | |
| HUE057817T2 (en) | Anti-lag-3 antibodies to treat hematological malignancies | |
| EP3331571A4 (en) | Compositions and methods to treat viral infections | |
| IL263859A (en) | Phosphoramidates for the treatment of hepatitis b virus | |
| EP3139954A4 (en) | Methods and compositions for treating hepatitis b virus infections | |
| RS64497B1 (en) | Oncolytic vaccinia virus | |
| EP3577132A4 (en) | Oncolytic virus therapy | |
| EP3288957A4 (en) | Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer | |
| EP3212658A4 (en) | 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer | |
| EP3454911A4 (en) | Oncolytic viruses comprising esrage and methods of treating cancer | |
| EP3307330A4 (en) | Method of treatment using oncolytic viruses | |
| HK1259445A1 (en) | Combinations to treat cancer | |
| IL291009A (en) | A new oncolytic virus platform to treat cancers with myxoma virus | |
| IL285221A (en) | Use of oncolytic viruses for the treatment of cancer | |
| GB201504251D0 (en) | Oncolytic herpes simplex virus infected cells | |
| EP3875119A4 (en) | Oncolytic virus for cancer therapy | |
| EP3664851A4 (en) | Combinations to treat cancer | |
| IL259781A (en) | Uses of pyrimido-pyridazinones to treat cancer | |
| EP3946373A4 (en) | Oncolytic myxoma virus expressing fast p14 to treat hematological cancer | |
| EP3490555A4 (en) | Methods and compositions to treat cancer | |
| EP3288576A4 (en) | Compositions and methods for treating cancer and persistent viral infections | |
| GB201816547D0 (en) | Oncolytic virus for the treatment of cancer | |
| HK1251490A1 (en) | Compositions and methods for immune-mediated cancer therapy | |
| AP2016009610A0 (en) | Live attenuated african horsesickness virus |